Key result
Intermittent ECG screening for AF proves cost-effective despite showing no three-year mortality benefit.
Why the study?
The study aimed to estimate the cost-effectiveness of intermittent ECG screening for AF in individuals aged 70-74 in primary care, alongside clinical outcomes at 3 years.
Does intermittent ECG screening for atrial fibrillation improve cost-effectiveness and clinical outcomes in 70-74-year-old individuals in primary care?
Cohort (n=290)
No
Does intermittent ECG screening for atrial fibrillation improve cost-effectiveness and clinical outcomes in 70-74-year-old individuals in primary care?
Hazard Ratio: 0.86 (95% CI 0.12–6.44)
Intermittent ECG screening for atrial fibrillation in 70-74-year-olds in primary care is highly cost-effective and associated with high anticoagulant adherence without increased mortality at 3 years.
May support AF screening cost-effectiveness in primary care septuagenarians; leaves open need for randomized outcome confirmation.
OBJECTIVES: The aim of this study was to estimate the cost-effectiveness of intermittent electrocardiogram (ECG) screening for atrial fibrillation (AF) among 70-74-year old individuals in primary care. We also aimed to assess adherence to anticoagulants, severe bleeding, stroke and mortality among screening-detected AF cases at three-year follow-up. METHODS: A post hoc analysis based on a cross-sectional screening study for AF among 70-74-year old patients, who were registered at a single primary care center, was followed for three years for mortality. Data about adherence to anticoagulants, incidence of stroke and severe bleeding among screening-detected AF cases, were collected from patient's records. Markov model and Monte Carlo simulation were used to assess the cost-effectiveness of the screening program. RESULTS: = 16) did not differ compared to the 274 individuals with no AF (hazard ratio 0.86, CI 0.12-6.44). Adherence to anticoagulants was 92%. There was no stroke or severe bleeding. The incremental cost-effectiveness ratio of screening versus no screening was EUR 2389/quality-adjusted life year (QALY) gained. The screening showed a 99% probability of being cost-effective compared to no screening at a willingness-to-pay threshold of EUR 20,000 per QALY. CONCLUSION: Screening for AF among 70-74-year olds in primary care using intermittent ECG appears to be cost-effective at 3-year follow-up with high anticoagulants adherence and no increased mortality.
No takes yet. Share an insight, caveat, or question.
Aronsson et al. (2022) conducted a cohort in Atrial fibrillation (n=290). Intermittent ECG screening vs. No screening / No AF was evaluated on Mortality (HR 0.86, 95% CI 0.12-6.44). Intermittent ECG screening for AF in 70-74-year-olds was cost-effective (EUR 2389/QALY), with no difference in 3-year mortality for screening-detected AF versus no AF (HR 0.86; 95% CI 0.12-6.44).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: